title: Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.
abstract: Metastasis suppressor genes (MSGs) have contributed to an understanding of regulatory pathways unique to the lethal metastatic process. When re-expressed in experimental models, MSGs block cancer spread to, and colonization of distant sites without affecting primary tumor formation. Genes have been identified with expression patterns inverse to a single MSG, and found to encode functional, druggable signaling pathways. We now hypothesize that common signaling pathways mediate the effects of multiple MSGs. By gene expression profiling of human MCF7 breast carcinoma cells expressing a scrambled siRNA, or siRNAs to each of 19 validated MSGs (NME1, BRMS1, CD82, CDH1, CDH2, CDH11, CASP8, MAP2K4, MAP2K6, MAP2K7, MAPK14, GSN, ARHGDIB, AKAP12, DRG1, CD44, PEBP1, RRM1, KISS1), we identified genes whose expression was significantly opposite to at least five MSGs. Five genes were selected for further analysis: PDE5A, UGT1A, IL11RA, DNM3 and OAS1. After stable downregulation of each candidate gene in the aggressive human breast cancer cell line MDA-MB-231T, in vitro motility was significantly inhibited. Two stable clones downregulating PDE5A (phosphodiesterase 5A), an enzyme involved in the regulation of cGMP-specific signaling, exhibited no difference in cell proliferation, but reduced motility by 47 and 66 % compared to the empty vector-expressing cells (p = 0.01 and p = 0.005). In an experimental metastasis assay, two shPDE5A-MDA-MB-231T clones produced 47-62 % fewer lung metastases than shRNA-scramble expressing cells (p = 0.045 and p = 0.009 respectively). This study demonstrates that previously unrecognized genes are inversely related to the expression of multiple MSGs, contribute to aspects of metastasis, and may stand as novel therapeutic targets.
authors.affiliation: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 37/Room 1126, 37 Convent Drive, Bethesda, MD, 20892, USA, natasciam28@gmail.com.
authors.forename: Natascia
authors.initials: N
authors.lastname: Marino
authors.forename: Joshua W
authors.initials: JW
authors.lastname: Collins
authors.forename: Changyu
authors.initials: C
authors.lastname: Shen
authors.forename: Natasha J
authors.initials: NJ
authors.lastname: Caplen
authors.forename: Anand S
authors.initials: AS
authors.lastname: Merchant
authors.forename: Yesim
authors.initials: Y
authors.lastname: Gökmen-Polar
authors.forename: Chirayu P
authors.initials: CP
authors.lastname: Goswami
authors.forename: Takashi
authors.initials: T
authors.lastname: Hoshino
authors.forename: Yongzhen
authors.initials: Y
authors.lastname: Qian
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
authors.forename: Patricia S
authors.initials: PS
authors.lastname: Steeg
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D045744:Cell Line, Tumor; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000235:genetics; D015536:Down-Regulation; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D009362:Neoplasm Metastasis / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D054706:Cyclic Nucleotide Phosphodiesterases, Type 5
references.citation: Int J Impot Res. 1996 Jun;8(2):47-52
references.pmid: 8858389
references.citation: Nat Rev Cancer. 2009 Apr;9(4):253-64
references.pmid: 19242414
references.citation: J Exp Med. 1999 Dec 20;190(12):1849-56
references.pmid: 10601359
references.citation: Cancer Res. 2005 Aug 15;65(16):7320-7
references.pmid: 16103083
references.citation: Rev Physiol Biochem Pharmacol. 1999;135:67-104
references.pmid: 9932481
references.citation: Cancer Res. 1988 Nov 15;48(22):6550-4
references.pmid: 2460224
references.citation: Pharmacogenet Genomics. 2005 May;15(5):295-301
references.pmid: 15864130
references.citation: Cancer Res. 2006 Feb 15;66(4):2264-70
references.pmid: 16489030
references.citation: Cancer Res. 2001 Jul 15;61(14):5644-51
references.pmid: 11454719
references.citation: Nature. 1998 Mar 12;392(6672):190-3
references.pmid: 9515965
references.citation: Mol Carcinog. 1998 Feb;21(2):111-20
references.pmid: 9496911
references.citation: Cancer Res. 2006 Jul 1;66(13):6497-502
references.pmid: 16818620
references.citation: Cell Cycle. 2012 Jul 1;11(13):2452-7
references.pmid: 22659842
references.citation: Pharmacogenet Genomics. 2005 Oct;15(10):677-85
references.pmid: 16141793
references.citation: Cancer. 2011 Dec 15;117(24):5509-18
references.pmid: 21638280
references.citation: Cancer Lett. 2013 Jan 28;328(2):207-11
references.pmid: 23059758
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3800-6
references.pmid: 15173088
references.citation: PLoS One. 2012;7(12):e51680
references.pmid: 23272139
references.citation: Int J Cancer. 2001 Sep;93(6):773-80
references.pmid: 11519036
references.citation: Drug Metab Rev. 2010 Feb;42(1):24-44
references.pmid: 19857043
references.citation: Cell Signal. 2004 Jun;16(6):681-92
references.pmid: 15093609
references.citation: J Clin Oncol. 2003 Sep 15;21(18):3454-61
references.pmid: 12972520
references.citation: Int J Cancer. 2003 Mar 20;104(2):147-54
references.pmid: 12569568
references.citation: J Cancer Res Clin Oncol. 2000 Feb;126(2):85-90
references.pmid: 10664247
references.citation: Eur J Cancer. 2010 May;46(7):1177-80
references.pmid: 20307970
references.citation: Int J Biochem Cell Biol. 2008;40(5):874-91
references.pmid: 18280770
references.citation: J Cell Biol. 1991 Apr;113(1):173-85
references.pmid: 2007622
references.citation: J Cell Sci. 2006 May 1;119(Pt 9):1683-90
references.pmid: 16636070
references.citation: Cancer Res. 2007 Aug 1;67(15):7238-46
references.pmid: 17671192
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):976-85
references.pmid: 11504793
references.citation: Int J Oncol. 2006 Oct;29(4):869-76
references.pmid: 16964382
references.citation: Lancet. 2007 May 19;369(9574):1742-57
references.pmid: 17512859
references.citation: J Biol Chem. 1998 Oct 16;273(42):27484-91
references.pmid: 9765278
references.citation: Cancer Res. 2000 Feb 15;60(4):950-6
references.pmid: 10706110
references.citation: Mol Cancer Ther. 2003 May;2(5):479-88
references.pmid: 12748310
references.citation: Cancer Res. 2005 Dec 1;65(23):10984-91
references.pmid: 16322247
references.citation: Am J Pathol. 2001 Jan;158(1):25-32
references.pmid: 11141475
references.citation: Mol Oncol. 2010 Aug;4(4):357-68
references.pmid: 20663721
references.citation: Cell. 2003 Jan 10;112(1):77-86
references.pmid: 12526795
references.citation: Cancer Res. 2002 Nov 15;62(22):6717-23
references.pmid: 12438272
references.citation: Biochem Biophys Res Commun. 2000 Aug 2;274(2):370-6
references.pmid: 10913345
references.citation: Apoptosis. 2006 May;11(5):725-38
references.pmid: 16532271
references.citation: Breast Cancer Res. 2005;7(6):R953-64
references.pmid: 16280042
references.citation: Nat Rev Drug Discov. 2014 Apr;13(4):290-314
references.pmid: 24687066
references.citation: Dev Cell. 2005 Nov;9(5):581-92
references.pmid: 16256734
references.citation: Curr Biol. 2002 Dec 23;12(24):2111-7
references.pmid: 12498685
references.citation: Lancet. 2005 Feb 19-25;365(9460):671-9
references.pmid: 15721472
references.citation: Ann Surg Oncol. 2006 Jun;13(6):802-8
references.pmid: 16614887
references.citation: Gynecol Oncol. 2001 Feb;80(2):121-7
references.pmid: 11161848
references.citation: Biochem Biophys Res Commun. 2007 Sep 14;361(1):169-75
references.pmid: 17658479
references.citation: Mol Ther. 2011 Mar;19(3):479-89
references.pmid: 21081901
references.citation: Cancer Genomics Proteomics. 2008 Jan-Feb;5(1):37-42
references.pmid: 18359978
references.citation: J Natl Cancer Inst. 2005 May 4;97(9):632-42
references.pmid: 15870434
references.citation: Blood. 2003 Jan 1;101(1):265-9
references.pmid: 12393651
references.citation: Nature. 2012 May 30;485(7400):S58-9
references.pmid: 22648501
references.citation: J Biol Chem. 1997 Apr 25;272(17):11629-35
references.pmid: 9111080
references.citation: J Neurosci. 2003 Jul 23;23(16):6452-9
references.pmid: 12878685
references.citation: Cell Mol Life Sci. 2000 Oct;57(11):1593-612
references.pmid: 11092454
references.citation: Pharmacogenetics. 2001 Jun;11(4):357-68
references.pmid: 11434514
references.citation: Mol Pharmacol. 2002 Sep;62(3):608-17
references.pmid: 12181437
references.citation: Nature. 2006 Jan 5;439(7072):95-9
references.pmid: 16397500
references.citation: J Clin Endocrinol Metab. 2004 Oct;89(10):5222-32
references.pmid: 15472229
references.citation: Annu Rev Immunol. 1997;15:797-819
references.pmid: 9143707
references.citation: Cancer Lett. 1997 Nov 11;119(2):149-55
references.pmid: 9570365
references.citation: Pharm Res. 2014 Jan;31(1):86-96
references.pmid: 23884568
references.citation: Trends Cell Biol. 2013 Feb;23(2):90-101
references.pmid: 23164733
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62
references.pmid: 24114568
references.citation: Endocrinology. 1999 Jul;140(7):3292-302
references.pmid: 10385426
references.citation: Cancer Res. 1993 Mar 15;53(6):1262-8
references.pmid: 8443806
references.citation: J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19
references.pmid: 22911670
references.citation: Cancer Res. 1999 Dec 15;59(24):6178-84
references.pmid: 10626810
references.citation: Cancer. 1996 Oct 1;78(7):1461-9
references.pmid: 8839552
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7392-7
references.pmid: 16243812
references.citation: Biochem Pharmacol. 1999 Oct 1;58(7):1097-107
references.pmid: 10484067
references.citation: Eur Urol. 2001 Aug;40(2):181-8; discussion 189-90
references.pmid: 11528196
references.citation: Cancer Res. 2007 Dec 15;67(24):11751-9
references.pmid: 18089805
references.citation: Mol Cancer. 2007 Jan 16;6:6
references.pmid: 17227585
references.citation: Nat Med. 2013 Sep;19(9):1104-9
references.pmid: 24013756
references.citation: Am J Pathol. 2008 Mar;172(3):809-17
references.pmid: 18276787
references.citation: PLoS One. 2010 Apr 19;5(4):e10108
references.pmid: 20419092
references.citation: Pharmacol Ther. 2006 Mar;109(3):366-98
references.pmid: 16102838
references.citation: Cancer Res. 2000 Feb 1;60(3):749-55
references.pmid: 10676663
references.citation: Cancer Biol Ther. 2005 Aug;4(8):805-12
references.pmid: 16082183
references.citation: Eur J Cancer. 2010 May;46(7):1283-9
references.pmid: 20303258
references.citation: J Cell Biochem. 2005 Feb 1;94(2):336-50
references.pmid: 15526282
references.citation: EMBO J. 2011 Aug 26;30(21):4500-14
references.pmid: 21873975
references.citation: Br J Pharmacol. 2008 Mar;153(6):1214-24
references.pmid: 18204475
references.citation: J Cell Biol. 2000 Jul 24;150(2):377-89
references.pmid: 10908579
references.citation: Cancer Cell. 2011 Jan 18;19(1):45-57
references.pmid: 21215707
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087